4/21/2021  9:59:55 PM Chg. +0.50 Volume Bid- Ask- Market Capitalization Dividend Y. P/E Ratio
65.97USD +0.76% 54,893
Turnover: 3.61 mill.
-Bid Size: - -Ask Size: - 3.52 bill.USD 0.00% 62.26

Business description

Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life.
 

Management board & Supervisory board

CEO
Robert G. Kramer
Management board
Richard S. Lindahl, Adam R. Havey, Atul Saran, Dr. Karen L. Smith, Fuad El-Hibri, Katy Strei, Sean M. Kirk
Supervisory board
Fuad El-Hibri, Dr. Jerome M. Hauer, Dr. Kathryn C. Zoon, Dr. Sue Bailey, Dr. Zsolt Harsanyi, General George A. Joulwan, Louis W. Sullivan, Marvin White, Robert G. Kramer, Sr., Ronald B. Richard
 

Company data

Name: Emergent Biosolutions Inc.
Address: 400 Professional Drive,Gaithersburg , Maryland 20879, USA
Phone: +1-301-795-1800
Fax: +1-301-795-1899
E-mail: -
Internet: www.emergentbiosolutions.com/
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 59.10%
IPO date: -

Investor relations

Name: Robert G. Burrows
IR phone: +1-240-631-3280
IR Fax: -
IR e-mail: BurrowsR@ebsi.com

Main Shareholders

Freefloat
 
59.10%
BlackRock, Inc.
 
13.00%
Fuad El-Hibri
 
10.70%
Vanguard Group, Inc.
 
8.90%
Intervac, L.L.C.
 
8.30%